• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, October 27, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

New assay selects patients with lung cancer for treatment with immune checkpoint inhibitors

Bioengineer by Bioengineer
February 13, 2019
in Biology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Molecular analysis of small, unfixed tissue samples collected using minimally invasive bronchoscopy can identify individuals with malignant disease and yield PD-L1 expression levels, reports The Journal of Molecular Diagnostics

Philadelphia, PA, February 13, 2019 – Immune checkpoint inhibitors, such as the anti-PD-1 antibody pembrolizumab, have become important tools for managing non-small-cell lung cancer (NSCLC). Assessing the level of programmed death ligand 1 (PD-L1) expressed by a tumor can help clinicians determine how the patient should be treated. A report in The Journal of Molecular Diagnostics describes a novel and rapid approach for quantifying PD-L1 expression levels in tumors that requires only small amounts of tissue that can be collected using minimally-invasive bronchoscopy techniques. This approach can also be used to discriminate malignant from benign tumors and identify mutational status, all of which can guide and refine therapeutic decisions.

“The emergence of lung cancer screening trials will result in greater demand to define the molecular nature of suspect lung nodules. This test has the potential to save considerable time and money in identifying patients who are most likely to benefit from checkpoint inhibitors such as pembrolizumab,” explained Steven Bozinovski, PhD, of the School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.

The paper describes a new streamlined approach for comprehensive molecular profiling of bronchial specimens suspected to be NSCLC. Upon collection of a bronchoscopy specimen using brush or biopsy radial probe endobronchial ultrasound (EBUS), a small amount of tissue is placed directly in nucleic acid stabilization buffer following rapid onsite evaluation of the malignant site. RNA and DNA are isolated from the specimen and an assay is performed to quantify the expression of matrix metalloproteinase-9 (MMP-9) and its endogenous inhibitor (TIMP3). The test itself can be performed very quickly, therefore, diagnosis of malignancy and PD-L1 status can be determined within hours following collection. The test and scoring can be readily automated to eliminate tester variability.

“In this study we demonstrate for the first time that the ratio of MMP-9:TIMP3 can accurately differentiate malignant from non-malignant tissue specimens without the need to fix tissue for histological assessment,” said Prof. Bozinovski. In one case, the MMP9:TIMP3 ratio was elevated more than 300 times while cytology was normal. Nine months later, repeat cytology confirmed that the tumor was indeed malignant.

The assay also quantifies PD-L1 transcript levels, which can have an important impact on the clinical management of NSCLC. Pembrolizumab has FDA approval for the frontline treatment of patients with advanced NSCLC whose tumors have 50 percent or greater PD-L1 expression as determined using the SP263 immunohistochemistry test. Patients with lower PD-L1 expression levels are more likely to benefit from a combination of pembrolizumab and chemotherapy. This study showed a strong positive association between transcript levels of PD-L1 as measured by the new assay and the FDA-approved SP263 immunohistochemistry.

According to the investigators, enough genomic DNA from the same specimen should be available to allow multi-panel targeted next-generation sequencing to assess the total mutational burden of the tumor. Importantly, this is possible because the tissue is unfixed, maintaining the integrity of DNA and RNA. In the current report, mutations were detected in the majority of EBUS tumor specimens, including TP53 gene mutations found in 10 of 15 NSCLC samples. Such information may further refine patient selection for a particular treatment regimen.

The test offers additional advantages including rapid turnaround time and automated analysis. “We believe our test should significantly enhance the diagnostic utility of EBUS-guided bronchoscopy specimens for the molecular testing of lung cancer patients,” noted Prof. Bozinovski.

###

Media Contact
Eileen Leahy
[email protected]
732-238-3628
http://dx.doi.org/10.1016/j.jmoldx.2018.10.001

Tags: cancerDiagnosticsMedicine/HealthMolecular BiologyPulmonary/Respiratory Medicine
Share12Tweet8Share2ShareShareShare2

Related Posts

Once Tadpoles Lose Their Lungs, They Never Regrow Them, Scientists Find

Once Tadpoles Lose Their Lungs, They Never Regrow Them, Scientists Find

October 27, 2025
Cloud Relay Boosts Blockchain Logging for IoT Fermentation

Cloud Relay Boosts Blockchain Logging for IoT Fermentation

October 27, 2025

How Uptake of DNA Fragments from Dying Cells Could Transform Mammalian Evolution and Genomics

October 27, 2025

Scientists Uncover Mechanism Behind Glucocorticoid Receptor Complexity

October 27, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1286 shares
    Share 514 Tweet 321
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    310 shares
    Share 124 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    197 shares
    Share 79 Tweet 49
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    134 shares
    Share 54 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Revolutionary Text-Based System Accelerates Hospital Discharges to Long-Term Care Facilities

New Cleveland Clinic Study Reveals That Up to 5% of Americans Harbor Cancer-Linked Genetic Mutations

Researchers Unlock the Mechanisms Driving Attachment Issues

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.